ORYZF (Oryzon Genomics) Marketable Securities: $0.00 Mil (As of Mar. 2026)


ORYZF Oryzon Genomics SA ORYZF
31 GF Score
Price $3.66
View Full Analysis

What is Oryzon Genomics Marketable Securities?

Oryzon Genomics ORYZF 31 Marketable Securities is $0.00 Mil as of Mar. 2026. GuruFocus rates ORYZF with a GF Score™ of 31/100.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Oryzon Genomics's Marketable Securities for the quarter that ended in Mar. 2026 was $0.00 Mil.

Oryzon Genomics's annual Marketable Securities stayed the same from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.00 Mil) but then increased from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($0.02 Mil).

Oryzon Genomics  (OTCPK:ORYZF) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Oryzon Genomics Marketable Securities Related Terms

Oryzon Genomics Marketable Securities Historical Data

* Premium members only.

The historical data trend for Oryzon Genomics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oryzon Genomics Marketable Securities Chart

Oryzon Genomics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.02

Oryzon Genomics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.02 0.00
ORYZF
31GF Score
Oryzon Genomics SA ORYZF
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oryzon Genomics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $0.00 Mil mean?
Oryzon Genomics (ORYZF) has a Marketable Securities of $0.00 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Oryzon Genomics and its competitors.
Is Oryzon Genomics' Marketable Securities too high?
Oryzon Genomics' current Marketable Securities is $0.00 Mil. Overall, Oryzon Genomics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Oryzon Genomics' Marketable Securities compare to VRTX and REGN?
Oryzon Genomics' Marketable Securities of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Oryzon Genomics and its competitors. Oryzon Genomics's current Marketable Securities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oryzon Genomics stock overvalued right now?
Oryzon Genomics (ORYZF) has a current Marketable Securities of $0.00 Mil. The current Marketable Securities is $0.00 Mil. Oryzon Genomics' overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Oryzon Genomics (ORYZF), the current Marketable Securities is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oryzon Genomics Business Description

Other Exchanges 0RDB:UKORY:SpainORN:Germany
Address Sant Ferran 74, Cornellà de Llobregat, Barcelona, ESP, 08940
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.
31GF Score

Get the complete analysis for ORYZF

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.66
Price